Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emricasan - Conatus Pharmaceuticals

Drug Profile

Emricasan - Conatus Pharmaceuticals

Alternative Names: IDN-6556; PF-03491390; PF-3,491,390; VAY 785

Latest Information Update: 29 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Idun Pharmaceuticals
  • Developer Conatus Pharmaceuticals
  • Class Amides; Aniline compounds; Antifibrotics; Antihypertensives; Fluorobenzenes; Hepatoprotectants; Pentanoic acids; Phenyl ethers; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Caspase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatic fibrosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Portal hypertension
  • Phase I/II Type 1 diabetes mellitus
  • Suspended Alcoholic hepatitis; Liver failure
  • No development reported Liver disorders
  • Discontinued Septic shock

Most Recent Events

  • 24 Jun 2019 Conatus Pharmaceuticals terminates the phase II ENCORE-LF trial in Non-alcoholic steatohepatitis in USA because the trial fail to meet primary endpoint (NCT03205345)
  • 24 Jun 2019 The phase IIb ENCORE-LF trial fails to meet its primary endpoint of event-free survival
  • 24 Jun 2019 The phase IIb ENCORE-PH trial fails to meet its primary endpoint of change in mean hepatic venous pressure gradient from baseline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top